SciELO - Scientific Electronic Library Online

 
vol.52 issue4Motor and functional recovery in patients with aphasia secondary to strokeLiver giant hemangioma author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Medicina

Print version ISSN 0034-7523

Abstract

MOREJON GARCIA, Moisés. Extended spectrum Beta-lactamase (ESBL). Rev cubana med [online]. 2013, vol.52, n.4, pp. 272-280. ISSN 0034-7523.

Beta-lactamase production is one of the major mechanisms of bacterial resistance. Beta-lactamases are enzymes capable of inactivating antibiotics of the beta-lactams family (penicillins, cephalosporins, monobactams and carbapenems). First descriptions were performed shortly after the use of penicillins began. With the emergence and repetitive use of new beta-lactamse: semisynthetic penicillin, cephalosporin, new variants of betalactamase were appearing until 1983, when extended spectrum betalactamases (ESBL) were described for first time. They are capable of inactivating cephalosporins of 3rd generation (ceftriaxone, cefotaxime, ceftazidime), and aztreonam. Although ESBL are more frequently described in Klebsiella pneumoniae and Escherichia coli strains, they can be produced by any Enterobacteriaceae, including bacilli fermenters No P. aeruginosa and A. baumannii.

Keywords : beta-lactamases; ESBL; bacterial resistance.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License